---
title: US healthcare system complexities and challenges
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

The United States healthcare system is exceptionally complex, a fact that often puzzles observers from other nations <a class="yt-timestamp" data-t="01:23:13">[01:23:13]</a>. It is a system filled with numerous intermediaries, making it challenging for a "functioning market" to interpret demand signals and for the end consumer to be truly treated as the customer <a class="yt-timestamp" data-t="01:25:31">[01:25:31]</a>.

## Key Parties in the Healthcare Value Chain
Understanding the flow of money and product requires identifying the numerous parties involved in a typical prescription drug transaction in the US <a class="yt-timestamp" data-t="01:23:36">[01:23:36]</a>:

*   **Drug Manufacturers:** These companies, like Novo Nordisk, are responsible for all research and development (R&D), production, and managing clinical trials to prove a drug's safety and efficacy <a class="yt-timestamp" data-t="01:26:00">[01:26:00]</a>.
*   **Distributors/Wholesalers:** Firms such as McKesson or Cardinal Health purchase drugs from manufacturers, warehouse them, and distribute them to pharmacies, taking on financial risk by holding inventory <a class="yt-timestamp" data-t="01:26:13">[01:26:13]</a>.
*   **Pharmacies:** These dispense drugs to consumers <a class="yt-timestamp" data-t="01:26:27">[01:26:27]</a>. Major chains like CVS and Walgreens have become significant players, often integrated with other parts of the system <a class="yt-timestamp" data-t="01:26:33">[01:26:33]</a>.
*   **Pharmacy Benefits Managers (PBMs):** These companies manage pharmacy benefits for a vast majority of Americans, with three dominant players covering about 80% of the market: Express Scripts, CVS Caremark, and OptumRx (owned by United Health Group) <a class="yt-timestamp" data-t="01:28:12">[01:28:12]</a>. PBMs negotiate discounts and rebates with drug manufacturers on behalf of insurance companies <a class="yt-timestamp" data-t="01:24:37">[01:24:37]</a>.
*   **Insurance Companies:** Pay for most of the drug costs, but often outsource price negotiation to PBMs <a class="yt-timestamp" data-t="01:24:17">[01:24:17]</a>.
*   **Employers:** Often involved in health plans, they may receive a share of the discounts negotiated by insurance companies <a class="yt-timestamp" data-t="01:24:55">[01:24:55]</a>.
*   **Patients:** The ultimate consumers, who typically pay a co-pay rather than the full list price of a drug <a class="yt-timestamp" data-t="01:24:08">[01:24:08]</a>.

## Systemic Challenges and Complexities

### Rebates and Opaque Pricing
A major mechanism for drug price negotiation is the rebate system <a class="yt-timestamp" data-t="01:29:44">[01:29:44]</a>. Manufacturers pay rebates to PBMs, which lowers the "net price" of the drug even if the "list price" remains the same <a class="yt-timestamp" data-t="01:29:50">[01:29:50]</a>. Eli Lilly has claimed that these discounts and rebates accounted for 75% of insulin's sticker price <a class="yt-timestamp" data-t="01:30:32">[01:30:32]</a>. While PBMs claim to pass most rebates to healthcare plans, and plans to employers, consumers rarely benefit directly from these rebates <a class="yt-timestamp" data-t="01:30:52">[01:30:52]</a>. This system is described as a "game of hide the sausage" <a class="yt-timestamp" data-t="01:31:22">[01:31:22]</a>, where demand signals from patients and clearing prices are lost in the "middleman mania" <a class="yt-timestamp" data-t="01:31:40">[01:31:40]</a>.

### High Costs and Misaligned Incentives
The US healthcare system consumed 17-18% of GDP in the 2010s, a significant increase from 5% in 1960 <a class="yt-timestamp" data-t="03:14:15">[03:14:15]</a>. Despite this, life expectancy has declined in recent years, primarily due to factors outside the direct control of the healthcare system, like mental health issues and drug overdoses <a class="yt-timestamp" data-t="03:16:26">[03:16:26]</a>.

One of the most [[economic_and_policy_dynamics_of_the_us_healthcare_system | pernicious issues]] is the misalignment of incentives due to short time horizons <a class="yt-timestamp" data-t="02:28:23">[02:28:23]</a>. The average American holds a job for 3.7 years, meaning private insurance companies only have an incentive to cover treatments that pay for themselves within that timeframe or are in high demand <a class="yt-timestamp" data-t="02:28:34">[02:28:34]</a>. Costly long-term complications of conditions like obesity, which might be prevented by early intervention, are often offloaded onto Medicare once patients turn 65 <a class="yt-timestamp" data-t="02:29:36">[02:29:36]</a>. This means the government, and thus taxpayers, are left "holding the bag" for long-term health costs <a class="yt-timestamp" data-t="02:32:04">[02:32:04]</a>.

### Stigma and Regulatory Hurdles
Historically, there has been a significant stigma against weight loss drugs and obesity itself, often viewed as a "personal responsibility problem" rather than a disease <a class="yt-timestamp" data-t="02:00:00">[02:00:00]</a>. The medical community thought it was impossible to create a safe and effective weight loss drug due to past disasters like Fen-Phen, which caused major heart damage <a class="yt-timestamp" data-t="02:01:30">[02:01:30]</a>. This led most pharmaceutical companies to avoid research and development in this area <a class="yt-timestamp" data-t="02:02:53">[02:02:53]</a>. As recently as 2005, Novo Nordisk's official position was that "obesity is primarily a social and cultural problem" with "no business for Novo Nordisk in that area" <a class="yt-timestamp" data-t="02:04:10">[02:04:10]</a>.

Compounding this, Medicare Part D, established in 2003 to cover prescription drugs for those over 65, is legally prohibited from paying for weight loss medications <a class="yt-timestamp" data-t="02:30:53">[02:30:53]</a>. Efforts to change this, including a bill introduced in 2013, have not passed <a class="yt-timestamp" data-t="02:31:01">[02:31:01]</a>.

### Drug Development Costs and Risk
Bringing a new drug to market is incredibly expensive and risky. On average, it costs $2.5 billion today, up from $40 million (inflation-adjusted) in 1953 <a class="yt-timestamp" data-t="03:11:03">[03:11:03]</a>. The probability of a preclinical study making it to market is only 8% <a class="yt-timestamp" data-t="01:58:07">[01:58:07]</a>. This high risk means that most drugs, even after approval, do not recoup their R&D costs <a class="yt-timestamp" data-t="03:13:02">[03:13:02]</a>.

This risk-reward dynamic incentivizes a "power law" distribution of profits: out of 100 drugs entering clinical development, only 10 make it to market, and *one* provides half of all profits <a class="yt-timestamp" data-t="03:12:32">[03:12:32]</a>. This makes Pharma the most classic example of the venture business, with high risk and high potential returns where winners must subsidize failures <a class="yt-timestamp" data-t="03:11:46">[03:11:46]</a>. As a result, many Pharma companies have shifted from mass-population drugs to specialty drugs for rare diseases, which, while having smaller addressable markets, can command prices in the millions of dollars per dose <a class="yt-timestamp" data-t="03:07:32">[03:07:32]</a>. This is because getting FDA approval is harder for conditions with existing alternatives, pushing companies towards "rare diseases" where the "low-hanging fruit has been picked" <a class="yt-timestamp" data-t="03:10:11">[03:10:11]</a>.

### System Design Mismatch: Acute vs. Chronic Illnesses
The US healthcare system, with its focus on hospitals, doctor visits, and acute interventions, was designed over the last century to treat acute and infectious diseases <a class="yt-timestamp" data-t="03:18:58">[03:18:58]</a>. This system has been largely successful in that regard, dramatically increasing life expectancy by curing infectious diseases <a class="yt-timestamp" data-t="03:19:14">[03:19:14]</a>.

However, the next frontier in healthcare is chronic illnesses, which develop over decades and are often undetectable for many years <a class="yt-timestamp" data-t="03:19:42">[03:19:42]</a>. Treating conditions like obesity leading to diabetes or cardiovascular health leading to heart attacks requires a fundamentally different approach, emphasizing prevention and continuous management rather than reactive care <a class="yt-timestamp" data-t="03:19:54">[03:19:54]</a>. The existing system, which consumes 18% of GDP, "may actually not make sense in this new world" <a class="yt-timestamp" data-t="03:20:07">[03:20:07]</a>.

### Non-Adherence to Treatment
A significant challenge, particularly with new drugs like GLP-1s, is patient non-adherence. Research indicates that as many as 68% of people stop taking these drugs after a year <a class="yt-timestamp" data-t="02:39:10">[02:39:10]</a>. Reasons include price, changes in insurance coverage, supply constraints, and unmanaged side effects <a class="yt-timestamp" data-t="02:39:17">[02:39:17]</a>. This raises concerns for employers and insurance companies about covering expensive treatments that patients may not continue, especially since the benefits often diminish upon discontinuation <a class="yt-timestamp" data-t="02:39:32">[02:39:32]</a>.

### Insulin Pricing Controversy
In 2021, US officials alleged that Novo Nordisk increased insulin prices by more than 600% between 2001 and 2019, in "lock step" with competitors, to the detriment of diabetics <a class="yt-timestamp" data-t="02:41:31">[02:41:31]</a>. While Novo Nordisk denied this, pointing to decreased net prices since 2017 <a class="yt-timestamp" data-t="02:41:47">[02:41:47]</a>, the controversy led to regulations, price caps, and the entry of biosimilars (generic versions of biologic drugs) into the market <a class="yt-timestamp" data-t="02:42:17">[02:42:17]</a>. This "perfect storm" made the insulin business significantly less attractive <a class="yt-timestamp" data-t="02:42:50">[02:42:50]</a>.

## Broader Societal Implications
The prevailing sentiment is that for every dollar invested into the healthcare system, the incremental utility is decreasing <a class="yt-timestamp" data-t="03:14:00">[03:14:00]</a>. While some argue that increased costs reflect more care delivered (e.g., more surgeries, preventative screenings) <a class="yt-timestamp" data-t="03:21:54">[03:21:54]</a>, the core issue remains a broken "free market" due to the numerous intermediaries and lack of transparency <a class="yt-timestamp" data-t="03:21:50">[03:21:50]</a>.

Pharma companies, despite often being criticized, are arguably the primary risk-takers and innovators in the healthcare ecosystem <a class="yt-timestamp" data-t="03:28:50">[03:28:50]</a>. Unlike pharmaceutical companies, whose net income can be "super spiky" due to the unpredictable nature of innovation, large health insurers' profits remained flat or grew even during the COVID-19 pandemic <a class="yt-timestamp" data-t="03:30:02">[03:30:02]</a>. This suggests that US health insurance functions more as "access" than true insurance, with taxpayers often funding large-scale losses <a class="yt-timestamp" data-t="03:29:57">[03:29:57]</a>. The extensive consolidation among insurers, PBMs, and even hospitals has led to localized monopolies or oligopolies that "obfuscated and insulated profits" <a class="yt-timestamp" data-t="03:30:41">[03:30:41]</a>.